Viemed (VMD) COO reports RSU vesting, phantom unit settlement

Rhea-AI Filing Summary

Viemed Healthcare, Inc. insider William Todd Zehnder, the Chief Operating Officer and a director, reported equity compensation transactions on 01/21/2026. He exercised 117,548 Restricted Stock Units (RSUs), each converting into one common share, and his directly held common shares increased as part of this vesting.

To cover related tax obligations from the RSU vesting, the company withheld 35,075 common shares at a per‑share value of $7.49, based on the market closing price on January 21, 2026. The filing also shows vesting and settlement of 8,554 cash‑settled phantom share units, economically equivalent to common shares, which resulted in both an acquisition and disposition of the same number of common shares for cash.

After these transactions, Zehnder directly owned 374,835 common shares, along with 235,094 RSUs and 17,107 phantom share units that remain outstanding and continue to represent future or cash‑settled economic exposure to Viemed common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZEHNDER WILLIAM TODD

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/21/2026		M		117,548	A	(1)	409,910	D
Common Shares	01/21/2026		F		35,075(2)	D	$7.49(3)	374,835	D
Common Shares	01/21/2026		M		8,554	A	(4)	383,389	D
Common Shares	01/21/2026		D		8,554	D	$7.49(3)	374,835	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/21/2026		M			117,548	(5)	01/21/2028	Common Shares	117,548	$0	235,094	D
Phantom Share Units	(4)	01/21/2026		M			8,554	(6)	01/21/2028	Common Shares	8,554	(4)	17,107	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.

3. Per share value is based on the market closing price of the common shares for January 21, 2026.

4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.

5. Restricted Stock Units (RSUs) granted to reporting person on January 21, 2025, which vest in three equal annual installments beginning on the first anniversary of the grant date.

6. Represents an award granted on January 21, 2025 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Viemed (VMD) COO William Todd Zehnder report in this Form 4?

The Form 4 shows that Chief Operating Officer and director William Todd Zehnder had 117,548 Restricted Stock Units vest into common shares and 8,554 phantom share units settle on 01/21/2026, along with related share withholding and dispositions.

Were the Viemed (VMD) transactions open-market stock sales by the COO?

The reported dispositions primarily reflect shares withheld to pay taxes on RSU vesting and share movements tied to cash-settled phantom share units at a reference price of $7.49 per common share, rather than discretionary open-market trading.

How many Viemed common shares does the COO hold after these transactions?

Following the transactions on 01/21/2026, William Todd Zehnder directly owned 374,835 common shares of Viemed Healthcare, Inc., as reported in the Form 4.

What ongoing equity awards does the Viemed COO still have after this Form 4?

After the reported activity, Zehnder continued to hold 235,094 Restricted Stock Units and 17,107 phantom share units, which provide future or cash-settled economic exposure to Viemed common shares under the company’s equity plans.

What does the $7.49 price represent in the Viemed (VMD) insider filing?

The $7.49 per-share value disclosed in the Form 4 is the market closing price of Viemed common shares on January 21, 2026, used to value shares withheld for taxes and shares disposed in connection with phantom share settlement.

What are RSUs and phantom share units in the context of Viemed’s compensation plans?

The filing explains that each RSU represents a right to receive one common share, while each phantom share unit is the economic equivalent of one common share and is settled in cash under Viemed’s Phantom Share Unit Plan, with vesting in three equal annual installments starting one year after the 01/21/2025 grant date.